Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author does not hold a position in BFLY.

← Back to Free Index

BFLY

Analysis as of: 2026-06-14

Butterfly Network, Inc.

Butterfly Network sells handheld ultrasound probes, cloud software, AI-enabled workflow tools, education, and licensing solutions for healthcare providers and selected partners.

ai healthcare medical devices semiconductors software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Portable imaging can compound beyond hardware

The opportunity is a shift from selling handheld probes to owning a regulated imaging workflow across hospitals, community care, and partners. If software attach and embedded licensing scale before larger vendors close the gap, value can roughly double by 2031.

Analysis

Thesis

Butterfly can more than double enterprise value by 2031 if it turns its handheld ultrasound lead into a regulated workflow and licensing layer: AI should make image capture easier, expand use into community care, and lift software attach, while Embedded adds high-margin revenue that matters disproportionately at its size.

Last Economy Alignment

AI lowers training and interpretation friction, which should expand where ultrasound can be used, and Butterfly controls both the chip-based device and parts of the workflow layer. It is helped by cheaper cognition, but it still faces bundling pressure from larger imaging vendors.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

2.4x (from 5 most recent analyses)

Reasoning

The upside comes from improving business quality more than from heroic market share assumptions. A larger installed probe base can pull through more enterprise workflow, compliance, and partner revenue, while AI reduces training friction and broadens use cases. If that mix shift happens, Butterfly can grow fast enough to offset some multiple compression from today’s premium starting point and still deliver a little more than a doubling in value.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The main risk is not whether Butterfly’s core technology works; it does. The real risk is whether management can convert a good handheld device into a broader, stickier operating layer before approvals, partner concentration, and OEM bundling blunt the transition. Because the stock already embeds some platform optimism, execution slippage matters more than raw end-market demand.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

No material Butterfly press release or SEC filing was identified in the last 7-10 days, so the setup still rests on the April 30 operating update.
Shares are trading near the top of the past year’s range, which means the next rerating likely needs milestone proof rather than stable guidance alone.
As of June 14, public confirmation of the first home and community care commercial agreement or Beam Steering API release had not been identified.

Forecast update

Upside compressed modestly because the equity already rerated from the prior run while the key platform milestones are still unconfirmed.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.51

They own a low-cost ultrasound chip and the workflow around it, so AI can make scans easier and push the device into more care settings. The risk is that bigger imaging vendors copy the handheld experience or bundle it into broader contracts before Butterfly owns enough of the trust and software layer.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$5.69

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research